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1. Introduction 
 
1.1 The definition of metabolic syndrome and its role in cardiovascular       
disease 
 
Metabolic syndrome is a combination of medical disorders that increase the risk of developing 
cardiovascular disease and diabetes. It affects one in five people and the prevalence increases 
with age. Some studies estimate the prevalence in the USA to be up to 25% of the population. 
 
The pathophysiology of metabolic syndrome is extremely complex and has been only 
partially elucidated. The most important contributing factors are weight, genetics, aging and 
sedentary lifestyle, i. e. low physical activity and excess caloric intake. 
 
The symptoms and features of metabolic syndrome are: 
• Fasting hyperglycaemia, diabetes mellitus type 2 or impaired fasting glucose, impaired 
glucose tolerance or insulin resistance. 
• High blood pressure 
• Central (also known as visceral) overweight with fat deposits mainly around the waist 
• Decreased HDL cholesterol and 
• Evaluated triglycerides. 
 
 
Various institutions offer different diagnostical criteria for the metabolic syndrome. One of 
the major definitions currently used was provided by International Diabetes Federation (IDF):  
 
Central obesity (defined as waist circumference with ethnicity specific values) and any two of 
the following: 
• Raised triglycerides: > 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid 
abnormality.  
• Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL 
(1.29 mmol/L) in females, or specific treatment for this lipid abnormality  
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• Raised blood pressure: systolic BP > 130 or diastolic BP >85 mm Hg, or treatment of 
previously diagnosed hypertension.  
• Raised fasting plasma glucose: (FPG)>100 mg/dL (5.6 mmol/L), or previously 
diagnosed type 2 diabetes. If FPG >5.6 mmol/L or 100 mg/dL, an oral glucose 
tolerance test (OGTT) is strongly recommended but is not necessary to define 
presence of the syndrome.  
# If BMI is >30 kg/m², central obesity can be assumed and waist circumference does not need 
to be measured. 
 
The World Health Organization(WHO) criteria (1999) requires for the presence of diabetes 
mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance, AND two 
of the following: 
• Blood pressure: ≥ 140/90 mmHg  
• Dyslipidaemia: triglycerides: ≥ 1.695 mmol/L and high-density lipoprotein cholesterol 
(HDL) ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)  
• Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), and/or body mass index 
> 30 kg/m2  
• Microalbuminuria: urinary albumin excretion ratio ≥ 20 mg/min or albumin:creatinine 
ratio ≥ 30 mg/g. 
NCEP 
The US National Cholesterol Education Program Adult Treatment Panel III (2001) requires at 
least three of the following: 
• central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 
36 inches(female) 
• dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl) 
• dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female) 
• blood pressure ≥ 130/85 mmHg 
• fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)2) 
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Various studies have shown that metabolic syndrome is associated with subsequent 
development of type 2 diabetes mellitus and cardiovascular disease (CVD). 
 
Cardiovascular disease and all-cause mortality are increased in men with 
the metabolic syndrome, even in the absence of baseline CVD and diabetes.3) 
A recent study with 12089 participants has demonstrated that men and women with the 
metabolic syndrome are 1.5 and 2 times more likely to develop coronary heart disease than 
control subjects after adjustment for age, smoking, LDL cholesterol, and race/ARIC center.4)  
 
 
 
Figure 1: Association of  metabolic syndrome with cardiovascular disease mortality3) 
 
 
Another study exposed a 24-fold risk of developing diabetes in men having 4 or 5 features of 
metabolic syndrome according to ATP III of NCEP compared with men with none.5) 
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Obesity, one of the main components present in the metabolic syndrome is associated with 
low grade inflammation of adipose tissue, resulting from chronic activation of innate immune 
system.6) 
 
1.2 Innate immune system and it’s component:  mannose-binding lectine 
 
The innate immune system is considered as the first line of host defence against infectious 
agents, which have penetrated the mechanical barriers of human organism. It is comprised of 
soluble and membrane bound proteins with a predefined specifity, in many cases involving 
carbohydrate moieties.7)  
 
The complement system plays a crucial role in the innate defense against common pathogens. 
Activation of complement leads to robust and efficient proteolytic cascades, which terminate 
in opsonization and lysis of the pathogen as well as in the generation of the classical 
inflammatory response through the production of potent proinflammatory molecules.8) 
 
The human collectin mannose binding lectine (MBL) is one of the important components of 
innate immunity. It provides first-line defence by its ability to bind sugar residues on the 
bacterial surface through its carbohydrate recognition domain and activates the complement  
pathway leading to lysis of bacteria independent of antibody.9) 
There is increasing evidence that MBL has a complex role in many diseases.10) 
 
1.2.1 MBL: structure 
 
Mannan-binding lectine is a plasma glucoprotein of the collectin-family, members of which 
bind to carbohydrates on the surfaces of microorganisms and particulate materials, including 
altered host material, such as apoptotic sells via their C-terminal lectin domains. MBL is 
produced by the liver; its serum levels are extremely variable, ranging from almost 0 to 
>5µg/mL in healthy humans. MBL deficiency is common (5% or more of the population, 
depending on the threshold concentration used to define deficiency).11) It is associated with 
severe and repeated infections in infants. 
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The polypeptide chain of secreted MBL is 228 amino acids long, not including the 20-residue 
signal peptide. It consists of a cystein-rich cross-linking region, collagen-like-region, a neck 
region and a C-terminal calcium-dependent carbohydrate-binding lectin domain. The neck 
region forms an α-helical coiled-coil structure which is supposed to promote trimerization of 
three polypeptides to form the subunit. The trimer is stabilized by hydrophobic interactions 
and inter-chain disulphide bonds within the N-terminal cystein-rich region. The commonest 
oligomeric form in humans appears to be a six-unit with an overall molecular mass of 
 18×25000 Da (see fig. 1).11) 
 
 
 
 
 
Figure 2: structure and organization of MBL 
 
 
1.2.2 MBL: binding specifity 
 
MBL shows selective and calcium (Ca2+)-dependent binding to terminal sugars D-mannose, 
L-fructose and N-acetyl-D-glucosamine (GlcNAc), but not to D-galactose and sialic acid. 
This selectivity relies on the presence of conserved amino acid residues within their CRDs. 
The CRD of MBL contains an EPN (Glu-Pro-Asn) amino acid motif that provides a 
preference for binding to sugars with equatorial 3- and 4-hydroxyl (OH) groups such as D-
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mannose, L-fructose, and GlcNAc. All these sugars are commonly found on the surface of 
many microorganisms.12)  
 
MBL leads to opsonisation and phagocytosis by polymorphonuclear cells. This binding also 
results in activation of the complement system in an antibody in C1q independent manner and 
requires MBL associated serine proteases MASP-1, MASP-2, MASP-3. Bound MBL 
associated with MASP-2 is able to promote C4 deposition and to form C3 convertase that 
leads to formation of membrane attack complex (MAC) and lysis of bacteria.9) 
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Figure 3: Mannose-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-
2) forming a complex that binds to sugar groups on microbial structures. Complement 
activation through the lectin pathway is initiated by C4 deposition and results in C3b 
formation and damage to microorganisms.13) 
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1.2.3 MBL: genetics  
MBL belongs to a family of collectin proteins, which are generally located on chromosome 10 
(q21-24). There are two MBL genes: MBL-1 and MBL-2. MBL-1 is a pseudo-gene and does 
not code for an active MBL protein. MBL- 2 consists of 4 exons and codes for the active  
MBL protein. The MBL-2 gene has three known mutations, all found on exon 1: allele B at 
codon 54, allele C at codon 57, and allele D at codon 52. These mutations lead to structural 
abnormalities in the collagenous triple helix and eventually failure to form a biological 
functional MBL protein and therefore they cause MBL deficiency. The wild-type is allele A. 
In addition to mutations in the promoter region of the MBL-2 gene, there are two mutations in 
the promoter region at -550(H/L, rs 11003125) and -221(Y/X, rs 7096206), which result in a 
decreased synthesis of the protein. The alleles interact with each other to form MBL secretor 
haplotypes, producing high, intermediary and low MBL levels. The combination of structural 
gene and promoter polymorphisms results in a dramatic variation of MBL concentration in 
apparently healthy individuals of up to 1000 fold.9)    
The three MBL2 variant alleles appear with different frequencies in different populations 
around the world. The B allele is virtually absent in Sub-Saharan West-Africa and occurs with 
low frequency in northern East-Africa, but is quite common among Caucasians (allele 
frequency 0.12–0.14) and Asians (allele frequency 0.10–0.25). The frequency in South 
American Indians may exceed 0.50. By contrast, the C allele is very common in Sub-Saharan 
Africans (0.10–0.30), rare among Caucasians (less than 0.03), and absent among Asians and 
American Indians. The frequency of the D allele is less frequent than the other two and 
appears to be confined to the Caucasians and northern East-African populations (allele 
frequency 0.06–0.08).14)  
 
1.2.4 MBL: serum levels 
 
MBL is primarily synthesized in the liver. Although it predominantly circulates as a serum 
protein, MBL has also been detected at various sites, for examples, in middle ear fluid, in 
synovial fluid of an inflamed joint, in amniotic fluid from 26 weeks gestation, and in 
nasopharyngeal secretion.11) MBL concentrations in umbilical cord blood are generally lower 
than in the circulation of adults, but there is a rapid rise during the first week of life. 15)  
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The combination of structural gene polymorphisms results in a dramatic variation in MBL 
concentration in apparently healthy individuals of up to 1000 fold (Caucasian<20-
10000ng/ml).9) The median level of MBL within a Danish Caucasian population was reported 
at 1.2µg/ml plasma for individuals homozygous for the wild type allele.7) 
 Currently, there is no definition of low MBL level.  
Unlike the archetypal acute phase proteins such as serum amyloid P- and C-reactive protein 
(CRP), whose levels can increase by 10-1000 fold during inflammation, MBL serum levels 
remain  relatively constant in individuals and determined by gene polymorphisms described 
above. Circulating levels of MBL only increase by 2-3 fold upon infectious and inflammatory 
challenge. However, during inflammation loss of vascular integrity results in leakage of MBL 
from the circulation into the inflamed site and hence it is reasonable to assume that more 
significant changes in the local MBL concentration might occur during inflammation states.12)  
 
1.2.5 Association of variant MBL serum levels with various diseases 
Various recently made studies have investigated correlations between varying MBL plasma 
serum levels on autoimmune and infectious diseases, metabolic and cardiovascular disorders. 
Both high and low MBL concentrations seem to have positive effects and disadvantages 
depending on the nature of the disease that the host is exposed to. 
Studies have demonstrated the importance of MBL in the anti bacterial defense. Pediatric 
patients with infections and with suspected immunodeficiencies have increased frequencies of 
MBL variant alleles.17) A strong clinical association between MBL variant alleles and 
meningococcal disease susceptibility has been shown in consecutive pediatric patients seen in 
a London hospital and in a United Kingdom-wide study of patients with meningococcal 
disease. Bacteriemia and pneumonia were significantly associated with decreased MBL levels 
(<500 µg/L) in chemotherapy-treated Danish hematology patients.13)   
Because of the high frequency of variant MBL alleles in different populations it has been 
speculated whether MBL deficiency could protect against certain infectious diseases. Based 
on the high frequency of MBL deficiency found in 56 Kenyan Africans, the authors suggested 
that low circulating levels of MBL may protect against infections with intracellular organisms 
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that display MBL ligands on their surface. The presence of MBL on the surface of parasites 
might allow for cellular uptake either directly via an MBL receptor or via receptors for 
complement fragments deposited on the parasite as a result of complement activation by the 
MBL pathway. In support to the protective effect of MBL deficiency, it was found that 
Ethiopians infected with M. leprae had a significant higher MBL than non-infected controls. 7)  
Several reports have presented evidence for the involvement of MBL in systemic lupus 
erythematodes (SLE). A significant correlation between the serum level of MBL and the risk 
acquiring SLE was also found. 7)  
In the study made in Glostrup University Hospital, in Copenhagen, Denmark, the presence of 
MBL variant alleles was found to be associated with the development of sepsis, severe sepsis, 
and septic shock.18) 
MBL 2 structural variant genotypes were found to be significantly associated with BMI of 
>25 and hypercholesterolemia. MBL2 exon 1 variant allele genotypes (A/O or O/O, where O 
indicates any of the variant alleles D, B or C) were more common among combined  
overweight and obese group (BMI >25.0) than among the normal weight group (38% vs. 
20%; p = 0.021.19)   
MBL seems to play dual role in occurrence and proliferation of cardiovascular disorders. 
While some studies propose cardioprotective role of high MBL serum circulation levels 
reducing the risk of myocard infarction, others claim that lectin pathway of complement 
activation leads to tissue damage in myocardial ischaemia/reperfusion (I/R) injury, and 
therefore, low MBL levels may be favorable in patient with cardiovascular disorders. 
 
In patients undergoing primary percutaneous coronary intervention, functional deficiency of 
complement MBL (serum MBL levels of or below 100 ng/mL) was associated with reduced 
mortality. 20) In a resent in-vivo study made on test animals monoclonal antibodies were raised 
against rat MBL.  Rats were subjected to 30 minutes of left coronary artery occlusion and  
4 hours of reperfusion. A pretreatment with the produced antibodies effected  postischemic 
myocardial reperfusion injury positively: significantly reduced myocardial creatine kinase 
loss (48%), infarct size (39%), and neutrophil infiltration (47%) were observed.21) 
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On the other hand,  MBL deficiency seems to be associated with bypass graft occlusion in 
patients with coronary heart disease.22) Furthermore, in a study with 76 Norwegian patients 
undergoing coronary-artery bypass, coronary-valve replacement surgery, 
or both and 100 blood-donor controls, an association of MBL deficiency with severe 
atherosclerosis was observed.23) Variant MBL alleles with lowered MBL serum levels were 
associated with increased carotid plaque area.24)  
 
High MBL may predict decreased likelihood of myocardial infarction. In a population-based 
Reykjawik study including 19381 participants, a cross-sectional group was selected from the 
original cohort (n=987). High MBL (>1,000ng/L) was associated with a greatly lowered odds 
ratio for MI (0.64, P<0.001). In the next cohort sample (n=1309), high MBL was associated 
with greatly decreased MI risk in diabetic (P=0.02) or hypercholesterolemic individuals 
(P=0.004). Also, the results of the study propose that hypercholesterolemic individuals with 
high MBL had enhanced risk of MI compared with participants with normal cholesterol 
levels, but the risk was much lower than that of hypercholesterolemic individuals with low 
MBL in both study groups25) 
 
According to a study with patients who attended the Steno diabetes center in Gentofte, 
Denmark, the mortality in type 2 diabetes was significantly higher among patients with MBL 
levels greater than or equal to 1000µg/L than among patients with levels less than 
1000µg/L.26) In contrast to this, low mannose-binding lectin genotype was found to be  
associated with future cardiovascular events in type 2 diabetic South Asians.27)  
MBL deposition was also found in human ruptured atherosclerotic plaques: Atherosclerotic 
lesions, stable and ruptured were collected during surgical procedures (carotid eversion 
endarterectomy) from individuals suffering end-stage symptomatic occlusive vascular disease. 
MBL deposits were located within the enlarged intima, along ill-defined necrotic segments of 
the atherosclerotic plaque.28)  
In a recent report authors emphasized a dual role of mannose-binding lectine in relation to 
carotid intima-media thickness in patients with rheumatoid arthritis. They found a strong 
association of quadratic term of serum MBL with intima-media thickness of the common 
carotid artery in 114 rheumatoid arthritis patients, reflecting a U-shaped relation. This finding 
suggests that both high and low MBL levels may be associated with increased subclinical 
atherosclerosis within the same diseased population.29) 
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2. Hypothesis 
  While metabolic syndrome and its feature increased visceral fat deposit is connected to 
chronic activation of innate immune system and MBL is a central player in the innate immune 
response, we assumed that mannan-binding-lectine might be an important diagnostic 
parameter of metabolic syndrome.  
                                                                                 
We hypothesize that circulating MBL levels in subjects with obesity and the MetS are 
associated with a distinctive cardiovascular risk profile. Thus, we evaluated in our study: 1) 
MBL levels in healthy lean controls compared to severely obese humans with and without the 
MetS; 2) the association of plasma MBL levels with cardiovascular risk profile and several 
markers of early atherosclerosis in the obese; and 3) the influence of substantial therapeutic 
weight loss on MBL concentrations. 
 
 
3. Methods 
 
3.1. Study population: “Obesity Weight Reduction and Remodeling Study” 
 
The rationale of the ongoing “Obesity Weight Reduction and Remodeling Study”, a 
prospective longitudinal study conducted since February 2006 at the University Hospital of 
Regensburg, Germany, is to evaluate excessive body fat for its pathogenic potential in terms 
of cardiometabolic diseases and to evaluate the effect of a considerable weight reduction on 
interactions in systems biology. In order to establish this, we are currently building up this 
study cohort to determine patterns of numerous metabolic and lipid/apolipoprotein 
abnormalities, lipidomics, adipokines, inflammatory markers, oxidative stress parameters and 
adhesion molecules, hormones of energy homeostasis, as well as subclinical atherosclerosis 
traits in obese with and without characteristics of the MetS, by extensively phenotyping very 
obese subjects before, during, and after a standardized weight reduction program, in addition  
to healthy lean subjects. Obese patients intending to participate in a weight reduction program 
are offered enrollment in this study prior to the start of the program. Patients are eligible for 
enrollment if they participate either in the standardized multimodal Optifast-52 weight 
reduction program (Nestle Healthcare®) provided by the Department of Psychosomatic 
Medicine at the University of Regensburg, or in a combined exercise and diet weight 
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reduction program offered by a local fitness gym. However, for the present study, only 
“Optifast participants” were considered. Patients were eligible for enrollment if they were 18-
59 years old, present with a BMI>30 kg/m2 and a constant body weight in the last 3 months, 
and if they signed declaration of consent. Patients were excluded if they had one or more of 
the following: more than 10% reduction of body weight in the last 6 month, cancer, 
pregnancy, therapy with steroids or thyroid hormones, known heart disease, known 
inflammatory bowel, rheumatiod or systemic diseases, known chronic renal failure, known 
liver diseases, mental disorders or addiction to drugs or alcohol. 
 
For comparison, healthy normal weight control subjects (BMI 20-25 kg/m2) of similar age 
and gender distribution are also studied. They are recruited by flyers, advertisements and 
friend referrals. 
 
The study was approved by the local Ethics Committee. All subjects had given their informed 
consent to their participation in the study. 
 
3.2 Standardized weight reduction program 
 
Optifast 52 (Nestle Healthcare) is a 52-week serious medical weight loss program 
encompassing diet, lifestyle changes, counseling, and exercise. The success of the program is 
documented and not only shows an average weight loss (52 pounds in 22 weeks), but a 
decrease in cholesterol, blood glucose and blood pressure21),22). Optifast is administered 
through clinics staffed with physicians trained in obesity management and is intended for use 
in patients that need to lose 50 or more pounds safely. Optifast users receive ongoing medical 
monitoring during the initial phase to assess progress, primarily due to the quick loss of a 
significant amount of weight. They also receive guidance and support in nutrition, behavior 
and exercise. During the initial 3-months “Active Weight Loss Phase”, which is portion 
controlled, calorically precise, and nutritionally complete, patients consume only meal 
replacements supplied by Optifast and water. These come in the form of shakes, nutritional 
bars and soups. It is an 800-calorie per day program that contains all the vitamins and 
minerals as recommended by the USDA. The low carbohydrate and fat content 
encourage a shift to fat breakdown and ketosis and the high protein content prevents the 
severe negative nitrogen balance associated with starvation and preserves lean body mass. 
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After the Active Weight Loss phase the following “Transition Period” will last 6 weeks, 
where meal replacements are gradually replaced by self-prepared meals. Menus and food 
recommendations are supplied to help during this transitional phase. Once the Transition is 
complete, the “Long Term Weight Management Program” begins. This will be the basis of a 
healthy lifestyle, utilizing a diet rich in produce, grains and low-fat proteins. Customized 
activity plans appropriate to the fitness level are part of the Optifast program and are 
considered to be essential to successful weight loss management. 
 
 
 
3.3 Phenotyping 
 
3.3.1 Anthropometric analysis 
 
All subjects were studied after a 12 hour overnight fast between 7:00 and 9:00 a.m.  
To measure waist circumference, the abdominal region of participants was cleared of closing 
or accessories to remove any pressure on the abdomen. If tight or restrictive clothing was 
worn, the belt was unlatched and their pants were loosed, the garment was lowered 
sufficiently. Participants were asked to stand with their feet shoulder-width apart and to cross 
their arms over their chest in a relaxed manner. Their hips were palpated in order to locate the 
top of the iliac crest. The measuring tape was placed on the level of the uppermost border of 
the iliac crest horizontally around the subject´s abdomen. The tape was kept horizontal from 
left to right and from back to front. (A mirror was used to facilitate this procedure). The tape 
was tightened around the abdomen gently without depressing the skin. The subjects were 
asked to relax and breathe normally. Subjects took 3-4 breaths before the measurement was 
taken. Measurement was taken from the 0 to the nearest millimeter at the end of a normal 
expiration. 
To measure hip circumference, all clothing and accessories except light underwear were 
removed. Participants were asked to stand with their feet about 15cm apart and their weight  
equally distributed on each leg. Participants were asked to breathe normally; the tape was 
tightened gently around the greatest hip circumference without depressing the skin. Subjects 
took 3-4 breaths before the measurement was taken. The reading of the measurement was 
taken at the end of gentle exhaling. 
 
20 
 
 To measure the weight of the probands correctly, shoes and bulky clothing were removed, 
pockets were emptied. The scale was balanced before participants stepped on it. Participants 
were asked to stand with their both feet in the center of the platform. After the scale had been 
in balance for 3-4 seconds, the weight was recorded to the nearest 0.1 kg. 
 
Height of the participants was measured with a standard SECA stadiometer. The distance 
from the floor of the platform to the highest point on the head was measured Participants were 
asked to remove their shoes and bulky clothes, to put their feet together and arms by their 
sides. Heels, buttocks and upper back of the participants were in contact with the wall. While 
the measurement was taken the subjects were facing directly ahead.  
 
Using the data gained above, waist-to-hip-ratio and body mass index (BMI) of the probands 
were evaluated. Waist-to-hip-ratio was calculated by dividing the waist circumference in 
centimeters with the hip circumference in centimeters of the subject. BMI was gained by 
dividing the individual's body weight by the square of his or her height. 
 
Blood pressure and the patient’s pulse have been taken after a sitting period of 5 minutes. 
The patient’s pulses (bilateral radial and dorsalis pedis arteria) were documented respecting 
rhythmen and character.  
 
In conclusion with the American heart association we measured blood pressure 3 times at 
both arms with an appropriate blood pressure cuff Welch Alynn with at least 60 seconds 
between the measurements. 
 
 
3.3.2 Body composition analysis 
 
Body composition was determined by bioelectrical impedance analysis (BIA) using 
Nutriguard-MTM (Data Input GmbH Darmstadt). It was used for measuring body fluid 
volumes, fat-free mass (FFM) and body cell mass. Impedance meters are applied in a supine 
position with four geltype electrodes, two voltage and two current ones, placed on the right 
foot and wrist. The BIA variables considered were resistance (R) and reactance (Xc). The 
bioimpedance index (BI) was calculated as the ratio height2/resistance.30) The instrument was 
regularly checked with resistors of known values. 
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3.3.3 Serological Analysis 
 
Adipokines and inflammatory markers. Fasting plasma adiponectin, leptin and resistin were 
measured using a commercially available enzyme-linked immunoassay (ELISA) kits (Bio 
Vendor®) and MBL was detected performing the ELISA kit Sanquin®. 
 
The concentration of high sensitive C-reactive protein (hsCRP) was determined by means of 
nephelometry (Nephelometer BN ProSpec®, Siemens). Interleukin-6 (IL-6) and Tumor 
necrosis factor-α (TNF-α) were measured by chemiluminescence detection (Immulite®, 
Siemens). 
 
Adhesions molecules and markers of early atherogenesis. Soluble CD40 ligand (sCD40 
ligand), matrix metallopeptidase 9 (MMP-9), Selectin, soluble intercellular cell adhesion 
molecule (sICAM) and soluble vascular cell adhesion molecule (sVCAM) were gauged using 
ELISA kits (R&D Systems®), while oxidized low density lipoprotein cholesterol (oxLDL) 
was measured performing the commercially available ELISA from Mercodia®. 
 
Glucose, Insulin and Lipids. Fasting plasma glucose, triglycerides (TG), high density 
lipoprotein cholesterol (HDL), low density lipoprotein (LDL) and free fatty acids (FFAs) 
were analyzed on an automated analyzer (ADVIA®, Siemens), while apolipoprotein A1 
(Apo-A1), apolipoprotein A2, apolipoprotein B (Apo-B) and lipoprotein (a) were measured 
by nephelometry (Nephelometer BN ProSpec®, Siemens). 
 
Fasting serum insulin was determined using chemiluminescence (ADVIA Centaur®, 
Siemens). 
 
Insulin sensitivity in the fasting state was assessed with homeostasis model assessment 
(HOMA) and calculated with the following formula: fasting serum glucose (nmol/L) x fasting 
serum insulin (mU/L) divided by 22.5, as described by Matthews et al.31) 
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3.3.4 Carotid Artery Studies.  
 
Ultrasonographic scans of the carotid artery were performed by expert sonographers who 
were specifically trained to perform the prescribed study examination. 
Ultrasound studies were performed using high-resolution B-mode ultrasound mainframes 
(Philips iE33) with the L11-3 MHz linear array transducer. 
Both common carotid arteries were scanned following a standardized protocol. The image 
was focused on the posterior (far) wall, and gain settings were used to optimize image quality. 
A resolution box function (zoom) was used to record an image 25 mm wide and 15 mm high. 
The intima media thickness (IMT) was measured as the distance between 2 parallel echogenic 
lines corresponding to the blood-intima and media-adventitia interface on the posterior wall of 
the artery. A moving scan with a duration of 5 seconds, which included the beginning of the 
carotid bifurcation and the common carotid artery, was recorded and stored in digital format 
on optical disks for subsequent off-line analysis. 
Digitally stored scans were manually analyzed by a reader blinded to participants' details. 
From the 5-second clip image, the best-quality end-diastolic frame was selected. From this 
image, measurements of the common carotid far wall were taken approximately 10 mm 
proximal to the bifurcation to derive maximal carotid IMT. 
 
3.3.5 Ankle-brachial index (ABI)  
  
The ABI was measured using the boso ABI 100 system (Bosch and Sohn, Germany) which 
allows blood pressure to be measured simultaneously on all four limbs. This simultaneous 
measurement produces a precise and reliable calculation of the ABI. The system measures 
oscillometrically without a Doppler probe or other sensor. Variations in individual measuring 
time are minimised by an intelligent inflation system and regulation of the deflation rate. 
Once the measurements have been taken, the results are transferred via a USB interface to a 
PC, where the application software calculates the ABI automatically for both sides. The lower 
ABI reading was used for further analysis. 
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3.3.6 Analysis of a resting metabolic rate via respiratory exchange ratio 
 
Resting metabolic rate (RMR) was measured by indirect calorimetry using a DeltatracTM 
system (DatexOhmeda) in a quiet environment. In supine position oxygen consumption and 
carbon dioxide production were determined for 30 min. Energy expenditure was derived from 
CO2 production and O2 consumption. The apparatus was calibrated with gas mixtures of 
known composition with 95% CO2 and 5% O2 before each test and the instrument was 
routinely checked. 
 
 
3.3.7 Evaluation of patient`s physical fitness 
 
A six-minute walking test (6-MWT) was performed as a measure of functional capacity. The 
6-MWT was conducted following a standardized protocol. A flat, obstacle-free corridor, with 
chairs placed on one side was used. Patients were instructed to walk as far as possible, turning 
180º every 35 m in the time of 6 minutes. Patients walked unaccompanied so as not to 
influence walking speed, and they were asked to walk as far as possible within 6 minutes. 
Patients were permitted to rest, if needed. At the end of the 6 minutes, the observer measured 
the total distance walked by the patient and noted the number and length of breaks, if breaks 
have been taken. The patient’s pulse was taken before and after the 6-minutes walk test. 
 
 
3.4 Definitions 
 
3.4.1 Definition of MBL deficiency 
 
MBL concentrations among healthy Caucasians vary from undetectable up to 10 000 μg/L 
with a median around 1 000 μg/L.25), 32) Single base mutations within exon 1 and several 
mutations in the promoter region of the MBL gene result in the interindividual differences in 
serum MBL levels. MBL deficiency is generally defined as serum levels < 500 ng/mL, but 
some groups have defined severe MBL deficiency as levels < 50 ng/mL and partial MBL 
deficiency from 50 ng/mL up to 1000 ng/mL.20), 33);34) 
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As there is no unique definition of functional MBL deficiency and clinical relevance may 
vary in different diseases, MBL levels <778 ng/mL were chosen for the differentiation in 
MBL deficient and MBL sufficient obese in our study. The cut off value 778 ng/mL was 
determined as the lower 95 confidence interval in our lean healthy control subjects. The 
median plasma MBL level in MBL deficient obese in our study was 245ng/mL (interquartile 
range 59-599), while the median concentration in MBL sufficient obese was 1704 (1218-
2341) ng/mL. 
 
3.4.2 Definition of metabolic syndrome 
 
MetS was diagnosed according to the Adult Treatment Panel III (ATP III).2)  It requires 
presence of central obesity with waist circumference ≥102 cm in men and ≥ 88 cm in women 
and dyslipidemia with values of triglycerides of ≥150 mg/dL, and HDL-cholesterol of 
<40mg/dL in men and < 50 mg/dL in women. Hypertension and hyperglycemia were 
diagnosed for values of blood pressure ≥ 130/85 mmHg and values of fasting plasma glucose 
≥ 110mg/dL. The MetS was diagnosed when at least three out of five metabolic abnormalities 
were determined. 
 
 
 
 
3.5 Statistical analysis 
 
Continuous variables are presented as mean ± standard deviation or median with its 
interquartile intervals (percentiles 25 and 75), when appropriate. 
 
Categorical variables were compared using the Fisher’s exact test. Continuous variables were 
compared using oneway anova for normally distributed variables (if significant, the Student’s 
t-test for the comparison of 2 groups, or the Tukey-Kramer post hoc test for multiple pairwise 
comparisons were used. For non-normally distributed variables we used the Kruskal-Wallis 
test, and the Dwass-Steel post-hoc test was used to make all possible pairwise comparisons, 
accounting for multiple testing. 
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The parametric paired t-test and the non-parametric Wilcoxon signed rank test were used to 
compare follow-up values of means from the same subjects, i.e. before and after weight 
reduction. Statistical significance was considered at the 0.05 level. All analyses were 
conducted using JMP, Version 9, SAS Institute Inc., Cary, NC. 
 
4. Results 
 
4.1 Patients characteristics at baseline 
 
According to the definition of metabolic syndrome (see above) we evaluated with the gained 
data the number of obese patients without (n=55) and with fully developed metabolic 
syndrome (n=41).  
 
The baseline characteristics of both obese participants with and without metabolic syndrome, 
as well as oft the lean control group are presented in table 1. Obese participants without  and 
with MetS  were of a similar age, had similar BMI (average of 39,7 without MetS vs 41,0 
with MetS), waist/hip-ratio ( 0,91 and 0,92 respectively) and fatmass (42,2% and 41,4% 
respectively). By definition, obese subjects with MetS had lower HDL cholesterol and higher 
triglyceride levels, as well as higher glucose, insulin, and HOMA-IR levels than obese 
without the MetS and lean controls. 
As expected, the percentage of subjects with diabetes among those with MetS was 
considerably higher than among obese participants without MetS (24% vs 2%).  
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Table 1: Baseline characteristics in healthy, lean controls, and obese subjects with and 
without the MetS 
                                          Controls                   Obese-no MetS  Obese-MetS 
                                          (n=25)                        (n=55)        (n=41) 
                                                                                                                
Sex n (% women)             15 (60)                      38 (69)                                        24 (59) 
Age (years)                       38±13                        42±14                                          45±12 
BMI (kg/m2)                   22.3±2.0                    39.4±7.7 c)                                41.0±7.9 c) 
Waist (cm)                        78±8                         120±19 c)                               121±18 c) 
Hip (cm)                            99±5                        131±14 c)                                 132±17 c) 
Waist/Hip                         0.79±0.06                 0.91±0.10 c)                             0.92±0.10 c) 
Fatmass (%)                     21.5±6.5                    42.2±8.7 c)                                41.1±7.5 c) 
RMR (cal./d)                     1539±221                  1973±522 c)                            2045±459 c) 
HDL chol. (mg/dL)            67±12 5                     8±15 c)                                   43±8 c), f) 
LDL chol. (mg/dL)           105±26                       113±34                                       122±36 
Triglyc. (mg/dL)                 73±27                        97±35                                   170±83 c), f) 
Diabetes n (%)                      0                                1 (2)                                          10 (24) 
Fasting Gluc. (mg/dL)        84±5                          92±11                                   125±55 c), f) 
Fasting Insulin (mU/L)       5.9±3.0                   18.2±14.8 b)                           26.4±16.9 c), d) 
HOMA-IR                           1.2±0.6                    4.3±3.9                                   8.8±7.9 c), f) 
Systolic BP (mmHg)          123±14                     137±19 b)                                 144±13 c) 
Diastolic BP (mmHg)          77±9                         83±12                                          86±9 b) 
 
 
RMR, resting metabolic rate; data are means ± SD; a): p<0.05 vs. Controls, b): p<0.01 vs. 
Controls, c): p<0.001 vs. Controls, d): p<0.05 vs. Obese, no MetS, e): p<0.01 vs. Obese, no 
MetS, f): p<0.001 vs. Obese, no MetS 
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Baseline adipocytokines, inflammmatory markers, and markers of atherosclerosis, and 
apolipoproteins in healthy lean controls, and obese subjects with and without the MetS are 
exposed at table 2.  
It can be observed below, that adiponectin levels in obese subjects were generally lower in 
both obese subgroups, with and without MetS, then in control group. Additionally, 
adiponectin was lower in the subgroup of obese with MetS, then in the obese subgroup 
without. Contrary could be observed in leptin concentration: it was significantly lower in 
controls, but also obese subjects with MetS had higher leptin serum levels then obese 
participants without MetS. Next, both subgroups of obese had statistically significant increase 
in hsCRP and intima media thickness in comparison with controls.  Obese subjects with MetS 
expressed higher oxLDL , Apo A1, Apo A2 and ApoB serum levels then both control cohort 
and obese group without MetS. 
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Table 2: Baseline adipocytokines, inflammmatory markers, and markers of 
atherosclerosis, and apolipoproteins in healthy lean controls, and obese subjects with 
and without the MetS 
 
                                          Controls                   Obese-no MetS Obese-MetS 
                                           (n=25)                       (n=55)     (n=41) 
                                                                           
Adiponect. (μg/mL)        12.6 (10.2-18.0)        10.6 (9.1-13.6) a)              9.5 (7.1-11.1) b) 
Leptin (μg/L)                   8 (2-12)                    48 (31-65) a)                     52 (30-65) c) 
Resistin (ng/mL)             4.7 (4.2-7.6)             5.3 (4.3-7.3)                      5.1 (4.2-7.2) 
Ghrelin (pg/mL)              75 (32-138)              11 (5-31) 2)                       18 (8-39) a) 
TNFα (pg/mL)                7.0 (5.7-9.2)              7.7 (6.8-10.5)                    10.0 (6.8-11.4) 
hsCRP (mg/L)                0.5 (0.3-1.9)              4.2 (2.6-11.0) c)                 5.2 (2.6-8.7) c) 
IL-6 (pg/mL)                   2.3 (2.0-3.3)             3.6 (2.2-4.7)                       3.6 (2.4-5.4) 
MMP9 (ng/mL)               354 (265-565)          532 (391-789) a)                461 (357-627) 
oxLDL (U/L)                   46 (40-56)               47 (38-62)                          57 (51-74) b), d) 
sCD40 (pg/mL)              6639 (5609-8670)     8040 (6300-10140)            7425 (6084-9340) 
Homocyst (μmol/L)        10.2 (8.8-11.1)          9.3 (7.7-11.4)                     10.5 (9.2-13.0) d) 
Serotonin (ng/mL)          107 (63-132)             95 (70-148)                        94 (73-126) 
Selectin (pg/mL)             28 (21-37)                38 (26-55) a)                        43 (35-60)  
sICAM (ng/mL)              245 (203-264)           239 (188-318)                    294 (235-347) b) 
sVCAM (ng/mL)             635 (571-863)          633 (503-759)                    654 (559-849) 
IMT (mm)                       0.50±0.16                  0.70±0.22 c)                      0.74±0.23 c) 
FFA (mmol/L)                 0.8 (0.6-1.5)              0.8 (0.6-1.1)                      0.8 (0.6-1.0) 
Apo A1 (mg/dL)              183 (159-196)          164 (146-188)                   143(130-158) c), f) 
Apo A2 (mg/dL)              35 (31-41)                34 (30-40)                         29 (26-32) c), f) 
Apo B (mg/dL)                80 (73-89)                91 (74-105)                       110 (86-127) c), e) 
Lp a (mg/dL)                   22 (15-53)                  31 (20-60)                         19 (12-34) 
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IMT = intima media thickness;  
a): p<0.05 vs. Controls, b): p<0.01 vs.Controls, c): p<0.001 vs. Controls, d): p<0.05 vs. 
Obese, no MetS, e): p<0.01 vs. Obese, no MetS, f): p<0.001 vs. Obese, no MetS 
 
 
 
Figure 4 exposes plasma MBL concentration in lean controls and obese patients without and 
with MetS at baseline. Beside the box-and-whisper plots representing the 10th, 25th, 50th, 75th 
and 90th percentiles, the means with its 95% confidence intervals are shown (dotted triangles). 
 
Mean MBL serum levels did not differ statistically significant in controls, obese subjects without and 
with MetS. 
 
 Figure 4. Plasma MBL concentration in lean control participants, obese subjects 
without metabolic syndrome and with present metabolic syndrome according to the 
definition of ATP III 
 
The cardiometabolic risk profile in MBL sufficient and MBL deficient obese subjects is given 
in table 3. Analogously, detailled blood biomarkers, IMT, and ABI across these both groups 
are shown in table 4. The median MBL plasma level in MBL deficient obese was 245 ng/mL 
(59-559 ng/mL) and in MBL sufficient obese 1704 ng/mL (1218-2341 ng/mL), p<0.0001). 
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Table 3: Cardiometabolic risk profile in MBL sufficient and MBL deficient obese 
                                     
                                  MBL deficient obese* MBL sufficient obese P Value 
                                               (n=40) (n=56)  
                                                                             
Sex n (% women)                  12 (30)                             22 (39)                            0.392 
Age (years)                            46±13                              44±14                              0.470 
BMI (kg/m2)                          38.5±7.4                          41.2±7.9                          0.099 
Waist (cm)                             118±16                            122±20                             0.257 
Hip (cm)                                129±13                             134±16                             0.129 
 
Waist/Hip                               0.92±0.08                        0.92±0.11                         0.958 
Fatmass (%)                           41.4±9.7                          42.2±6.7                           0.664 
RMR (cal./d)                          1968±527                         2024±468                        0.605 
HDL chol. (mg/dL)                 51±13                               53±15                              0.494 
LDL chol. (mg/dL)                 111±33                             121±36                             0.163 
Triglyc. (mg/dL)                     130±74                            127±69                             0.847 
Diabetes n (%)                        3 (8)                                8 (14)                               0.351 
Fasting Gluc. (mg/dL)           105±43                             107±37                             0.756 
Fasting Insulin (mU/L)           20.1±16.5                         22.9±16.0                        0.400 
HOMA-IR                               5.2±4.7                             6.9±7.2                            0.193 
Systolic BP (mmHg)              139±18                             140±16                            0.826 
Diastolic BP (mmHg)             83±11                                85±11                             0.457 
 
RMR, resting metabolic rate; data are means ± SD; MBL levels in MBL deficient obese 
245ng/mL (59-559 ng/mL) vs. MBL sufficient obese 1704 ng/mL (1218-2341 ng/mL), 
p<0.0001; *MBL deficiency, MBL<778 ng/mL (corresponding to the lower 95% CI in 
controls). 
 
In both MBL sufficient and deficient obese, mean fatmass, waist/hip ratio, triglucerid levels 
and fasting glucose were almost identical. MBL deficient obese subjects expressed even 
slightly lower HOMA-IR (5,2±4,7) than MBL sufficient cohort (6,9±7,2). 
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Table 4: Adipocytokines, inflammmatory markers, markers of atherosclerosis and 
apolipoproteins in MBL sufficient and MBL deficient obese 
 
                                         MBL deficient obese*      MBL sufficient obese          P Value 
                                         (n=40)                         (n=56) 
 
Adiponectin (μg/mL)             10.5 (8.0-14.0)             9.9 (7.0-12.1)                     0.349 
Leptin (μg/L)                          53 (30-65)                   49 (32-66)                           0.891 
Resistin (ng/mL)                    5.4 (4.4-7.5)                5.0 (4.3-7.1)                        0.627 
Ghrelin (pg/mL)                     12 (7-46)                     16 (5-29)                             0.857 
TNFα (pg/mL)                        8.8 (6.5-10.8)              8.7 (6.9-11.3)                     0.546 
hsCRP (mg/L)                         5.1 (2.7-12.7)             5.2 (2.5-8.8)                        0.809 
IL-6 (pg/mL)                           3.6 (2.2-5.4)                3.2 (2.2-5.2)                       0.923 
MMP9 (ng/mL)                       481 (353-810)             501 (394-699)                    0.932 
oxLDL (U/L)                           53 (36-63)                   56 (44-75)                          0.080 
sCD40 (pg/mL)                       7364 (5999-9939)        8193 (6632-9701)              0.251 
Homocystein (μmol/L)           10.2 (8.8-12.2)             9.6 (8.0-11.4)                      0.209 
Serotonin (ng/mL)                  98 (73-132)                  95 (68-138)                         0.876 
Selectin (pg/mL)                     41 (32-56)                    41 (24-59)                           0.752 
sICAM (ng/mL)                      266 (190-330)              266 (206-335)                     0.806 
sVCAM (ng/mL)                     643 (505-836)              647 (544-769)                     0.973 
IMT (mm)                               0.75±0.26                     0.70±0.20                            0.345 
ABI                                         1.03±0.17                     1.06±0.23                             0.474 
FFA (mmol/L)                        0.8 (0.6-1.0)                  0.8 (0.7-1.1)                        0.139 
ApoA1 (mg/dL)                     152 (137-179)                153 (137-182)                     0.997 
Apo A2 (mg/dL)                    31 (27-35)                      32 (27-37)                           0.429 
Apo B (mg/dL)                       96 (76-115)                   97 (82-121)                         0.688 
Lp a (mg/dL)                           25 (12-36)                     32 (18-60)                           0.148 
 
IMT, intima media thickness; ABI, ankle-brachial index; data are medians (interquartile 
range) or means ± SD; MBL levels in MBL deficient obese 245 ng/mL (59-559 ng/mL) vs. 
MBL sufficient obese 1704 ng/mL (1218-2341 ng/mL), p<0.0001; *MBL deficiency, 
MBL<778ng/mL (corresponding to the lower 95% CI in controls). 
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Observing the table 4, it can be recognized that MBL sufficient and deficient obese subjects 
express only minor differences in their cardiometabolic risk profile. The markers of 
atherosclerosis were almost identical in both subgroups (as example, hsCRP serum levels 
were at 5,1 and 5,2 in MBL deficient and sufficient obese respectively), no statistically 
relevant differences could be observed in apolipoproteins. Among the markers of 
atherosclerosis, solely the IMT was slightly higher in MBL deficient obese subjects compared 
to participants with no MBL deficiency (0,75 mm and 0,70 mm respectively).  
 
4.2 Evaluation of patients parameters at a 3-months-folow up  
 
The changes in selected anthropometrical data, cardiovascular risk profile, adipocytokines, 
inflammatory parameters, and markers of early atherosclerosis achieved by diet in obese 
patients after substantial weight loss in percentage in comparison to the baseline investigation 
are presented in figure 5. The most prominent changes achieved by the diet could be detected 
for leptin (>60%), adiponectin (>50%), hsCRP, selectin, and HOMA-IR. 
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Figure 5. Changes of selected anthropometric parameters, adipocytokines, inflammatory 
parameters achieved in the group of obese patients by diet are exposed in % in 
comparison with baseline investigation. 
 
For more detailed analysis of obese subjects we subdivided the group in three nearly equal 
subgroups according increasing tertiles of different components of metabolic traits. The group 
in the left column presents lower, the group in the right column correspondingly, higher 
concentrations of various parameters of  metabolic syndrome and atherosclerosis.  
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 We observed the 3 subgroups at a subject of MBL level in association to different serum 
parameters of MetS. Results can be observed at figure 5. In each subgroup MBL levels were 
similar before and after marked weight loss. 
 
 
Fig. 6. Serum MBL concentration in severely obese subjects at baseline and post diet, 
whereby subjects were divided into subgroups according to increasing tertiles of 
different components of metabolic traits. In each subgroup MBL levels were similar 
before and after marked weight loss 
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It can be recognized that MBL is not associated to any of the chosen parameters: HOMA-IR, 
HDL cholesterol, adiponectin, leptin, hsCRP, TNFα, oxygenized LDL. 
 
Figure 7 exposes the MBL levels of both obese and control groups at a baseline in comparison 
to those attending a 3-month follow up investigation. The mean MBL concentration in obese 
participants at a baseline was 1132,93 ±1047,30, while at the 3-month follow up  
1207,94±961,25 (p=0,6397). Analogously, in lean controls, the concentrations at baseline and 
at a 3-month follow up were 1370,73±1182,08 and 1413,70±1267,71. It is recognizable that 
despite of various changes in MBL concentrations in single individuals, the mean MBL level 
remained nearly unchanged before and after dietary intervention in the obese group, as well as 
in the control group without a dietary intervention. 
Furthermore, the MBL serum levels do not differ significantly between the obese and lean 
participants.   
 
 
                          Baseline                 3-MFU Baseline 3-MFU 
Fig. 7.  The individual effect of weight loss on serum MBL levels in severely obese 
compared to subsequent measurements in healthy lean controls. 
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5. Discussion 
 
Mannose-binding lectin is a serum protein that plays a central role in the innate immune 
response.12)  
The genetic inheritance has the largest influence on circulating MBL concentration. MBL 
serum levels are relatively constant. 
 
However, several studies claimed a 2-3 fold increase of MBL serum levels during an acute 
phase response.35)  
 
Obesity appears to be associated with a low-grade inflammation of white adipose tissue. 
Therefore we hypothesized that obesity may be associated to an activation of native immune 
system and the MBL circulating levels differ from those of lean subjects. However, in the 
population of obese participants with or without evidence of metabolic syndrome we 
quantified similar serum MBL concentrations to those of the control group.  
 
Furthermore, our study has shown that MBL serum level can not be affected by dietary 
intervention and weight reduction: MBL concentration was not associated to weight loss in 
the population of obese participants. 
 
The reason why differing MBL concentrations were not observed in obese subjects is that 
MBL increase may conduct when a certain degree of inflammation has been reached and a 
considerable activation of the innate immune system is required. Increased MBL levels after a 
major surgery described by Thiel in 35) can be probably explained as exactly the type of 
challenge for a native immune system of its host. 
 
MBL insufficiency has been linked to many specific disorders, although the findings of 
similar studies have sometimes been contradictory. 
 
Whereas in early childhood and in immunodefficient patients a native immune system and its 
major component MBL undoubtedly plays a crucial role and therefore MBL deficiency may 
lead to severe health disorders, the role of MBL in other diseases is controversial. Both high 
and low serum MBL concentrations may be advantageous depending on the disease and the 
type of pathogen the host is exposed to.     
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One popular hypothesis or assumption is that MBL insufficiency is only clinically relevant in 
the context of another coexisting immune deficiency. This view has not been conclusively 
confirmed or refuted, but enough data have been collected to support it as a sensible working 
hypothesis. Firstly, it is undoubtedly true that the majority of individuals in the general 
population with low MBL levels, or even very low MBL levels, are healthy. Secondly, 
clinical symptoms ascribed to MBL insufficiency have sometimes been found in combination 
with a specific laboratory-defined defect: IgG subclass deficiency (Aittoniemi et al., 1998)36), 
a chemotaxis defect (Ten et al., 1999)37) and neutropenia induced by the chemotherapy (Neth 
et al., 200138), Peterslund et al., 200139)) are examples.16)  
 
The comparison of results on the baseline investigation and in the 3-month-follow-up 
investigation in the group of obese subjects reveals a significant improvement both of 
anthropometric and serologic parameters. Furthermore, in the interviews with observers the 
majority of obese participants claimed to notice an improvement in their health related quality 
of life after weight loss. 
 
Using factor analysis to reveal correlations of MBL serum levels and various serum 
parameters of a metabolic syndrome, we have found no associations with the most 
parameters: insulin, fasting serum glucose, HDL, total adiponectin, selectin, triglycerides. 
 
While no significant differences in MBL circulating levels in obese and lean subjects were 
found, we observed in the control group associations between low MBL and cardioprotective 
parameters such as adiponectin, fasting glucose, HDL, LDL, ApoA2, ApoB and resistin.  
 
Furthermore, we divided the obese subjects into subgroups according to increasing tertiles of 
different components of the MetS or plasma biomarkers and compared the MBL levels before 
and after weight loss. No statistically relevant changes of MBL plasma concentrations were 
observed both in the subgroup without and with fully developed MetS. 
 
Considering the fact that MBL serum concentration was similar in obese population and in the 
control group on the baseline and expressed no significant changes after significant 
improvement of anthropometric and serologic parameters in obese group associated with the 
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weight loss, we summarize that MBL cannot be used as a diagnostical parameter of metabolic 
syndrome. 
 
Although the MBL concentrations in the whole population of obese patients and controls 
remained nearly unchanged, in single cases MBL levels varied in a same person on a baseline 
and on 3-month-follow-up considerably. During the observation period our participants were 
not exposed to any major surgeries and seemingly did not have severe inflammation that can 
explain MBL serum level variations. Therefore we suppose that other factors than 
inflammation in acute phases are able to influence the MBL serum concentration in 
individuals. Long-term measurements of MBL serum levels in participants with and without 
medicamental intervention may be of a great interest in order to evaluate factors other than 
genetic expression that may be able to modify the MBL levels in individuals. 
 
Contrary to our findings a recent study presented an association between MBL, BMI and 
insulin resistance, whereby MBL levels were positively correlated with insulin action40), 
despite the patients in this study (n=434) did not have a fully developed metabolic syndrome. 
The same study also assessed a correlation between weight loss (in consequence of 
biliopancreatic diversion) and insulin sensitivity in a secondary longitudinal analysis 
comprising 10 obese patients ; a correlation of serum MBL concentration change with insulin 
sensitivity, but not with changes in BMI was asserted.  With respect to the latter findings, the 
constrained power in a longitudinal analysis of only ten subjects should be recognized. 
 
Furthermore, our results are in accordance to another report, showing that a massive loss of 
excessive body weight did not affect serum MBL, visfatin and TNF-α, despite of significant 
changes in parameters of metabolic syndrome.41) Moreover, in a large study with 987 
participants, MBL levels did not correlate with diabetes mellitus, BMI, or total serum 
cholesterol.25)  
 
Another study undertaken  by Aarhus University Hospital, Denmark included 36 non-diabetic 
obese subjects who received a low-calorie diet for 8 weeks. A common weight loss of 13.5 kg 
was achieved. Similar to our study, the relationship between the MBL serum level, obesity 
and insulin resistance was investigated. No correlations were found between weight loss and 
changes in MBL, nor between changes in insulin resistance and MBL.42) 
 
39 
 
To our knowledge the present study is the first correlating MBL concentrations with markers 
of early atherogenesis, oxidative stress parameters, adhesions molecules, or atherogenic 
lipoproteins, in addition to traditional components of the MetS. 
 
 
Various arbitrary cutoff levels have previously been used to define insufficient MBL levels 15), 
43). Several previous studies are based on MBL genotyping44)-46), but DNA samples were not 
available in this study. Our cutoff was determined statistically, based on the MBL distribution 
in healthy control subjects, and approximates other reports.33), 45), 47)   We have also performed 
statistical analysis using the cutoffs generally found in the literature with MBL deficiency 
defined as serum MBL< 1000ng/mL and MBL< 500ng/mL and achieved similar results to 
those presented in our study (data are not shown).  
 
 
In a recent study, MBL was detected using the ELISA kit Sanquin® ELISA kit for in vitro 
quantitative analysis of mannose binding lectin in human serum (or plasma). The kit has a 
minimum detection level of  9.0 ng/mL and possesses an intra-essay variation of 6.1%48). We 
performed repeated determinations to ensure high quality of measurements and achieved a 
high conformity of results. 
 
The strengths of the present study are detailed phenotypic characterization of participants 
including both anthropometric data, serological atherosclerosis and diabetes markers ECG, 
ECH and Carotid ultrasound imaging, and an achievement of a considerable changes in 
cardiometabolic risk profiles by valuable weight loss. 
 
It is worth mentioning, that although MBL seems to be unsuitable as a prognostic factor 
of  insulin resistance, our findings lead us believe that a combination of waist circumference 
above 129cm and low adiponectin are strongly associated with impaired insulin action in 
obese participants. 
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6. Summary 
 
MBL is a major component of a native immune system. It plays a considerable role in the 
activation of the immune cascade.  MBL deficiency is common and occurs in a high 
percentage of population. 
 
A large number of frequent studies describe associations of circulating MBL serum levels to 
various diseases. Depending on the art of disorder, MBL deficiency seems play either 
negative, or, in some cases, protective role, preventing the excessive activation of the innate 
immune system.  
 
 Obesity is associated with low grade inflammation of adipose tissue, resulting from chronic 
activation of the innate immune system.  
 
Chronic low-grade inflammation, as found in obesity and particularly in the MetS, may 
influence different components of the innate immune system that in turn lead to insulin 
resistance and type 2 diabetes, dyslipidemia, endothelial dysfunction and atherosclerosis. 
In a present study, we investigated the association of MBL serum levels with obesity the 
possibility to influence the MBL concentration via dietary intervention, the association of 
MBL with atherosclerotic parameters as well as metabolic syndrome and insulin resistance. 
 
We enrolled 96 severely obese patients, with and without MetS, who participated in a 
standardized weight loss program “Optifast”, and 25 lean (20<BMI<25), seemingly healthy 
person as a control group.  
 
 MBL serum levels of participants were examined in association with markers of insulin 
resistance, dyslipidemia, adipokines, and subclinical atherosclerosis before and after marked 
weight loss (20 ± 8 kg after 3 months) in the obese group and in the control group with no 
dietary intervention. The results of both groups were analyzed and compared to each other. 
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The MBL serum levels among lean and obese participants did not differ on the baseline 
investigation independently on presence of a MetS. Furthermore, the MBL serum 
concentration remained nearly equal both in the control group and among the obese 
participants after dietary intervention in the 3-month-follow up investigation. 
 
In severely obese subjects there was no significant difference concerning cardiovascular risk 
profile, apolipoproteins, inflammatory and metabolic parameters, and markers of endothelial 
dysfunction and atherosclerosis between subjects with functional MBL deficiency           
(MBL < 778 ng/mL) and MBL sufficient obese (MBL ≥ 778 ng/mL). 
  
Our findings suggest that plasma levels of MBL do not differ between healthy lean and 
severely obese subjects. There seems to be no association between MBL serum concentration 
and markers of insulin resistance, dyslipidemia, adipokines, and early atherosclerosis in 
severely obese patients before and after marked weight loss. 
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Zusammenfassung 
 
Das metabolische Syndrom ist eine Kombination von kardiovaskulären Risikofaktoren und ist 
charakterisiert durch die vier Hauptkomponenten, abdominelle Adipositas, Bluthochdruck 
(Hypertonie), veränderte Blutfettwerte (Dyslipidämie), und Insulinresistenz. Aufgrund des 
gleichzeitigen Vorhandenseins mehrerer atherogener Risikofaktoren gilt es als bedeutender 
Risikofaktor für kardiovaskuläre Erkrankungen, insbesondere für die koronare 
Herzerkrankung. Auch das Risiko, an einem manifesten Typ 2 Diabetes mellitus zu 
erkranken, ist um das vielfache erhöht. Frühzeitig  sind bei Vorhandensein eines 
metabolischen Syndroms Zeichen einer endothelialen Dysfunktion nachweisbar. 
 
Inzwischen ist bekannt, dass bei Vorhandensein eines metabolischen Syndroms im 
Fettgewebe proinflammatorisch wirksame Moleküle sezerniert werden,  die möglicherweise 
eine bedeutende Rolle bei der Entwicklung einer Insulinresistenz sowie Atherosklerose 
spielen. Desweiteren sind in die Pathogenese der Atherosklerose auch Faktoren des 
angeborenen Immunsystems involviert. 
 
Eines der Bestandteile des angeborenen Immunsystems ist  das Plasmaprotein Mannose-
bindendes Lektin (MBL). Als Akut-Phaseprotein  ist es in der Lage, Komplement zu 
aktivieren und somit systemische Inflammation zu aggravieren. 
Die MBL- Konzentration ist individuell hauptsächlich genetisch präterminiert und schwankt 
zwischen sehr geringen, nicht messbaren Werten bis über 5 µg/mL. Die Plasmaspiegel sind 
relativ konstant; sie können jedoch im Rahmen von Akut-Phasereaktionen auch um das 2-3 
fache ansteigen. MBL könnte eine Rolle in der Interaktion zwischen Adipositas bzw. dem 
metabolischen Syndrom und kardiovaskulären Folgeerkrankungen spielen. Die Ergebnisse 
diesbezüglich bislang publizierter Untersuchungen zu kardialen Endpunkten sind allerdings 
widersprüchlich. 
 
Das Ziel folgender Arbeit war festzustellen, ob bei  Patienten mit morbider Adipositas und 
somit vorhandener chronischer „low-grade-inflammation“ ein Zusammenhang zwischen den 
Parametern des metabolischen Syndroms und der endothelialen Dysfunktion bzw. der frühen 
Atherogenese einerseits und der MBL-Plasmakonzentration andererseits besteht. Desweitern 
sollte der Frage nachgegangen werden, ob durch eine Verbesserung der metabolischen 
Situation, wie sie durch eine Lifestyle-Intervention bzw. durch eine Teilnahme an einem 
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standardisierten Gewichtsreduktionprogramm erreicht werden kann, die MBL-
Plasmakonzentration beeinflusst werden kann. 
 
Zu diesem Zweck wurde eine prospektive Untersuchung an 96 sehr adipösen Probanden 
durchgeführt, die an dem Gewichtsreduktionsprogramm „Optifast-52“ (Nestle Healthcare) 
teilnahmen. Zusätzlich wurden 25 vermeintlich gesunde, normalgewichtige Kontrollpersonen 
untersucht. Alle Teilnehmer wurden einer ausführlichen  klinischen und laborchemischen 
Phänotypisierung unterzogen. Parameter des metabolischen Syndroms, der endothelialen 
Dysfunktion und der frühen Atherogenese wurden im longitudinalen Verlauf vor, während 
und nach Gewichtsreduktion mit den Plasma-MBL-Konzentrationen korreliert.  
 
Dabei waren die MBL-Konzentrationen bei gesunden Kontrollpersonen mit denjenigen der 
sehr adipösen Probanden vergleichbar, und zwar unabhängig vom Vorhandensein eines 
metabolischen Syndroms. Desweiteren zeigte eine ausführliche klinische Charakterisierung 
der Studienteilnehmer keine wesentlichen Unterschiede bei adipöse Probanden mit hohen und 
niedrigen Plasma MBL-Konzentrationen. Detaillierte Subgruppenanalysen konnten ebenfalls 
keine statistisch signifikante Assoziationen zwischen den untersuchten Parametern und den 
MBL-Konzentrationen identifizieren. 
Auch führte die die hypokalorische, die mit einem Gewichtsverlust von 20±8 kg verbunden 
war, zu keiner Änderung der MBL-Plasmaspiegel. 
 
Zusammenfassend scheint es keinen Zusammenhang zwischen MBL und Parametern 
des metabolischen Syndroms sowie der Atherogenese zu geben. MBL beeinflusst weder 
kardiovaskuläre Risikofaktoren, noch hat eine Lifestyle-Intervention Auswirkung auf 
die MBL-Plasmaspiegel. 
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